Amgen Assist 360/FIRST STEP Program
Amgen offers assistance to patients through Amgen Assist 360, Amgen FIRST STEP, and the Amgen Safety Net Foundation. A complete list of Amgen oncology products and their related assistance progtrams is provided in the Table.
Amgen Assist 360
Amgen Assist 360 provides resources such as Amgen Reimbursement Counselors to conduct benefit verifications and Amgen Nurse Navigators who can help find resources that are most important to your patients. Please visit Amgen's website for more information. To enroll your patient in the Amgen Nurse Navigator program, download the enrollment form.
Amgen FIRST STEP
This program can help your eligible commercially insured patients cover their out-of-pocket prescriptions costs, including deductible, coinsurance, and copayment. Patients may be eligible if they:
- Have been prescribed 1 or more qualifying Amgen products
- Have private commercial health insurance that covers medication costs for the qualifying Amgen product(s)
- Are not participating in any federal-, state-, or government-funded program such as Medicare, Medicare Advantage, Medicare Part D, Medicaid, Medigap, Veterans Affairs, the Department of Defense, or Tricare
- Do not seek reimbursement for value received from the Amgen FIRST STEP program from any third-party payers, including flexible spending accounts or healthcare savings accounts.
Patients can register for this program by visiting AmgenFirstStep.com. For more information from an Amgen FIRST STEP representative, call 888-4ASSIST (888-427-7478).
Amgen Safety Net Foundation
This foundation assists patients who are uninsured or their insurance plan excludes the prescribed Amgen medicine or its generic/biosimilar. Patients may be eligible if they:
- Have lived in the United States or its territories for 6 months or longer
- Satisfy income eligibility requirements
- Have Medicare Part D with product coverage but cannot afford their out-of-pocket costs.
To apply to the Amgen Safety Net Foundation, please visit our website, and select the prescribed medicine.
TABLE Amgen Oncology/Supportive Care Drugs
Drugs
Indications
Patient support programs
Drug
Aranesp (darbepoetin alfa)
Indications
Chemotherapy-induced anemia
Patient support programs
Drug
Blincyto (blinatumomab)
Indications
Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia; CD19-positive B-cell precursor acute lymphoblastic leukemia in first or second complete remission, with minimal residual disease
Patient support programs
Drug
Epogen (epoetin alfa)
Indications
Chemotherapy-induced anemia
Patient support program
Drug
Imlygic (talimogene laherparepvec)
Indications
Melanoma with unresectable cutaneous, subcutaneous, or nodal lesions
Patient support programs
Drug
Kanjinti (trastuzumab-anns)
Indications
Treatment of HER2-overexpressing breast cancer; treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma
Patient support programs
Drug
Kyprolis (carfilzomib)
Indications
Relapsed or refractory multiple myeloma, as a single agent or in combination with dexamethasone or with lenalidomide and dexamethasone or with daratumumab and dexamethasone
Patient support programs
Drug
Lumakras (sotorasib)
Indications
Treatment of adult patients with KRAS G12C–mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least 1 prior systemic therapy
Patient support programs
Drug
Mvasi (bevacizumab-awwb)
Indications
Patient support programs
Drug
Neulasta (pegfilgrastim)
Indications
Growth factor support for patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs
Patient support programs
Drug
Neupogen (filgrastim)
Indications
Growth factor support for patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs
Patient support programs
Drug
Nplate (romiplostim)
Indications
Patient support programs
Drug
Prolia (denosumab)
Indications
Increase bone mass (1) in men with prostate cancer receiving androgen-deprivation therapy, or (2) in women with breast cancer receiving adjuvant aromatase inhibitor therapy
Patient support programs
Drug
Riabni (rituximab-arrx)
Indications
Patient support programs
Drug
Vectibix (panitumumab)
Indications
Treatment of wild-type RAS metastatic colorectal cancer as either first-line in combination with FOLFOX or as monotherapy following disease progression after prior treatment with chemotherapy
Patient support programs
Drug
Xgeva (denosumab)
Indications
Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastasis from solid tumors; unresectable giant-cell tumor of the bone; hypercalcemia of malignancy refractory to bisphosphonate therapy
Patient support programs
NSCLC indicates non–small‑cell lung cancer.
Mvasi (bevacizumab-awwb) Indications
Treatment of recurrent glioblastoma; treatment of persistent, recurrent, or metastatic cervical cancer, in combination with chemotherapy; treatment of metastatic colorectal cancer, in combination with chemotherapy or after disease progression with a bevacizumab-containing regimen; treatment of unresectable, locally advanced, recurrent, or metastatic nonsquamous NSCLC, in combination with carboplatin and paclitaxel; treatment of metastatic renal-cell carcinoma, in combination with interferon-alfa
Nplate (romiplostim) Indications
Treatment of patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy; treatment of pediatric patients ≥1 year of age with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy
Riabni (rituximab-arrx) Indications
Treatment of adult patients with non-Hodgkin’s Lymphoma (NHL), including relapsed or refractory, low-grade or follicular, CD20-positive B-cell NHL as a single agent; previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy; in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; non-progressing, low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy; previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or other anthracycline-based chemotherapy regimens; treatment of adult patients with chronic lymphocytic leukemia (CLL), including previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide
Report Broken Links
Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?
Help us fix it! Report broken links here.